PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA.

被引：0
|
作者：
Yang, F. [1 ]
Zhu, M. [1 ]
Toroghi, M. [1 ]
Putluri, D. [1 ]
Yan, H. [1 ]
Davis, J. [1 ]
DiCioccio, A. [1 ]
机构：
[1] Regeneron Pharmaceut, New York, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
OV-002
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [41] Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
    Wiseman, GA
    White, CA
    Witzig, TE
    Gordon, LI
    Emmanouilides, C
    Raubitschek, A
    Janakiraman, N
    Gutheil, J
    Schilder, RJ
    Spies, S
    Silverman, DHS
    Grillo-López, AJ
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3281S - 3286S
  • [42] Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
    Wagner, HN
    Wiseman, GA
    Marcus, CS
    Nabi, HA
    Nagle, CE
    Fink-Bennett, DM
    Lamonica, DM
    Conti, PS
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (02) : 267 - 272
  • [43] Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
    Postema, EJ
    Oyen, WJG
    Boerman, OC
    Corstens, FHM
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 853 - 853
  • [44] Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma
    Chinn, PC
    Leonard, JE
    Rosenberg, J
    Hanna, N
    Anderson, DR
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 15 (05) : 1017 - 1025
  • [45] Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
    Morschhauser, Franck
    Leonard, John P.
    Fayad, Luis
    Coiffier, Bertrand
    Petillon, Marie-Odile
    Coleman, Morton
    Schuster, Stephen J.
    Dyer, Martin J. S.
    Horne, Heather
    Teoh, Nick
    Wegener, William A.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3346 - 3353
  • [46] Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (Rituximab)-treated non-Hodgkin's lymphoma
    Nomura, Shosaku
    Ishii, Kazuyoshi
    Kamitsuji, Yuka
    Uoshima, Nobuhiko
    Ishikawa, Emiko
    Kitayama, Hitoshi
    Hayashi, Kunio
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2007, 13 (02) : 206 - 212
  • [47] Dissection of GvHD and GvL by FBTA05, a novel trifunctional anti-CD3 x anti-CD20 antibody
    Buhmann, R.
    Stanglmaier, M.
    Simoes, B.
    Menzel, H.
    Peschel, C.
    Ruf, P.
    Lindhofer, H.
    Kolb, H. -J.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S123 - S123
  • [48] Combination anti-CD20 immunotherapy and pretargeted anti-CD20 radioimmunotherapy (PT-RAIT) of non-Hodgkin lymphoma (NHL) shows improved efficacy
    Goldenberg, David M.
    Karacay, Habibe
    Chang, Chien-Hsing
    Rossi, Edmund A.
    McBride, William J.
    Sharkey, Robert M.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [49] Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
    Krasniqi, Ahmet
    D'Huyvetter, Matthias
    Xavier, Catarina
    Van der Jeught, Kevin
    Muyldermans, Serge
    Van der Heyden, Jose
    Lahoutte, Tony
    Tavernier, Jan
    Devoogdt, Nick
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (12) : 2828 - 2839
  • [50] IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with pretreated low-grade non-Hodgkin's lymphoma.
    Schwandt, KU
    Bremer, K
    ANNALS OF ONCOLOGY, 2000, 11 : 105 - 105
12345